SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Layoffs
Dewpoint Slashes Headcount by 70% as Cash Runway Runs Out
In December 2024, Dewpoint Therapeutics CEO Ameet Nathwani said the biotech’s cash runway would last until the third quarter of 2025.
August 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Earnings
Gilead Confident in PrEP Franchise Even Amid Preventive Task Force Uncertainties
The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV PrEP Yeztugo—that insurers must cover. A recently postponed meeting has raised concerns that Health Secretary RFK Jr. could abolish or overhaul the group.
August 8, 2025
 · 
2 min read
 · 
Tristan Manalac
A contemporary art collage depicting a giant ear listening to a message bubble while covering it with a hand. The concept of taking in a useful experience or overhearing a new idea.
Mergers & acquisitions
Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity
There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.
August 7, 2025
 · 
2 min read
 · 
Tristan Manalac
Man in low poly style before important choice stock illustration, decision, triple, three
Earnings
Lilly Faces Triple Threat of Drug Pricing Pressure as CEO Emphasizes Value
From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with Novo Nordisk, pricing was the number one issue for Eli Lilly on its second quarter earnings call.
August 7, 2025
 · 
3 min read
 · 
Annalee Armstrong
Hiring collage showing HR checking applicant information
Job Trends
Hiring Outlook: Latest Job, Application Numbers Highlight Tough Job Market
Higher competition for fewer roles remains the status quo for biopharma professionals, based on BioSpace data. Additionally, the U.S. Bureau of Labor Statistics has reported that recent job growth is lower than previously believed.
August 7, 2025
 · 
4 min read
 · 
Angela Gabriel
Contemporary art collage. Purple hand holding fan of dollar bills against bright yellow background. stock photo
Cancer
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds
Strand Therapeutics’ lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing the immunomodulatory protein IL-12.
August 7, 2025
 · 
2 min read
 · 
Tristan Manalac
Eli Lilly's headquarters in Indianapolis
Obesity
UPDATE: Lilly’s Oral Weight Loss Drug Underdelivers, But Executives See Real World Opportunity
Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ bear scenario for the oral med. Executives brushed off the concerns and said the drug will still have a wide advantage on the market.
August 7, 2025
 · 
4 min read
 · 
Annalee Armstrong
Courtesy of Sarepta Therapeutics
Earnings
Despite Safety Drama, Sarepta Beats Q2 Estimates—But No Thanks to Elevidys Sales
Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.
August 7, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH CRESSET
From Chat Bots to World Order: The Race for the 21st Century’s Operating System
In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses the emerging geopolitical battle for AI supremacy and global AI governance with Mutlu Dogruel, VP of AI and Mark Mackey, CSO of Cresset.
August 7, 2025
 · 
1 min read
 · 
Lori Ellis
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS